Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Abbott Laboratories (ABT) vs TKO Group Holdings Inc (TKO) Price & Performance

Abbott LaboratoriesTrade
TKO Group Holdings IncTrade

Price performance (Past 24H)

Key statistics

Abbott Laboratories vs TKO Group Holdings Inc — how do they compare? Abbott Laboratories trades at $109.23 (market cap $187.95B), while TKO Group Holdings Inc trades at $194.36 (market cap $14.24B). The key difference: Abbott Laboratories is far larger — about 13.2× TKO Group Holdings Inc's market cap, and Abbott Laboratories pays the higher dividend (2.32%). Which is the better fit depends on your goals.

ABTTKO
Market Cap
$187.95B$14.24B
Sector
HealthTechnology
52-Week High
$136.62$224.96
52-Week Low
$82.57$176.49
Enterprise Value
$214.96B$18.60B
Dividend Yield
2.32%1.6%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Abbott Laboratories

Abbott Laboratories (ABT) trades at $109.74, up 1.8% on the day, with a bullish technical signal from moving averages and strong analyst consensus. Recent financials show revenue growth to $44.33 billion in 2025, though net income declined to $6.52 billion. Key developments include a CE Mark for dual glucose-ketone sensors, enhancing its diabetes care portfolio. The stock is near its 52-week high, with support at $108 and resistance at $109.

Outlook remains positive with a consensus price target of $120.70, offering ~10% upside. Risks include competitive pressures in medical devices and macroeconomic volatility. Earnings beats in Q1 and Q2 2026 support growth, but margin compression and high P/E of 35.15 warrant caution for value-focused investors.

TKO Group Holdings Inc

TKO trades at $186.56, down 0.39% on the day, with a bullish technical signal and strong analyst support. The company reported record Q2 2026 revenue of $1.55 billion (up 18% year-over-year) and raised full-year guidance, though it missed EPS estimates. Valuation ratios are elevated with a P/E of 66.46, but profitability metrics show improvement. Recent corporate actions include an $800 million share repurchase and a $0.79 dividend payment.

The outlook is positive driven by media rights growth and live events, with a consensus price target of $228.17 implying 22% upside. Risks include earnings volatility and institutional selling. Wall Street sentiment remains strongly bullish with 89% buy ratings.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Abbott Laboratories

Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.

Read more on ABT

About TKO Group Holdings Inc

TKO Group Holdings is a premium sports and entertainment company that serves as the parent entity for the Ultimate Fighting Championship (UFC) and World Wrestling Entertainment (WWE). Formed through a seismic merger orchestrated by Endeavor, TKO leverages a combined global fanbase of over 1 billion to drive massive revenue through media rights, global live events, and a unified sponsorship platform, effectively monopolizing the professional combat sports landscape.

Read more on TKO